Complement C5 defines 2 chronic spontaneous urticaria endotypes with distinct autoantibody profiles and omalizumab responses: The INCA study
Annals of Allergy, Asthma & Immunology · 2026-09
DOI: 10.1016/j.anai.2026.08.033 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Annals of Allergy, Asthma & Immunology, 2026-09. Verfasst von João Luís Alves Marcelino und 14 weiteren Autor:innen. Beteiligte Einrichtung: Allergology and Clinical Immunology Department, Hospital de São Bernardo, Unidade Local de Saúde da Arrábida, Setúbal, Portugal; Institute of Allergo…. Hauptthemen laut MEDLINE: Omalizumab, Chronic Urticaria, Autoantibodies, Complement C5. Die Arbeit nennt 58 Literaturangaben. Gefördert von: Deutsche Forschungsgemeinschaft.
Abstract (Originalsprache)
BACKGROUND: Complement activation has long been implicated in chronic spontaneous urticaria (CSU), but the underlying mechanisms and its clinical relevance remain unclear. OBJECTIVE: To investigate the roles of complement C3, C4, C5, and C5a in CSU and their associations with immunologic profiles and response to omalizumab. METHODS: We conducted a multicenter cross-sectional study involving 159 patients with CSU from 5 Allergology and Clinical Immunology centers in Portugal. Clinical data, patient-reported outcomes, complement fractions, total IgE and IgG/IgE autoantibodies were assessed. Patients were stratified according to serum C5 levels. RESULTS: Serum C5 showed a bimodal distribution, identifying 2 distinct subgroups that broadly aligned with the immunologic features previously described for autoallergic and autoimmune CSU. The low/normal C5 group (n = 61) had lower C3 and C5a, higher total IgE, lower frequencies of autoantibodies (IgG and IgE antithyroid peroxidase and IgG anti-IgE), and an 89% response rate to standard-dose omalizumab. The high C5 group (n = 98) exhibited elevated C3 and C5a, higher rates of autoimmune thyroid disease, a higher prevalence of IgG and IgE autoantibodies, and a 36% response rate to standard-dose omalizumab. C5a showed a similar bimodal distribution and association with omalizumab response. CONCLUSION: Serum C5 identifies 2 biologically distinct CSU subgroups: a low/normal C5 group characterized by higher total IgE, limited complement activation, and a high response rate to omalizumab and a high C5 group characterized by lower IgE, enhanced complement activation, increased autoimmune burden, and a low response rate to omalizumab. These findings suggest that C5 may represent a clinically useful biomarker for therapeutic stratification.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Allergology and Clinical Immunology Department, Hospital de São Bernardo, Unidade Local de Saúde da Arrábida, Setúbal, Portugal; Institute of Allergology, Charité - Universitätsmedizin Berlin, corporate member of Freie…
- Institute of Allergology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany; Fraunhofer Institute for Tra…
- Allergology and Clinical Immunology Department, Hospitais da Universidade de Coimbra, Unidade Local de Saúde de Coimbra, Coimbra, Portugal.
- Allergology and Clinical Immunology Department, Hospitais da Universidade de Coimbra, Unidade Local de Saúde de Coimbra, Coimbra, Portugal; Faculty of Medicine, University of Coimbra, Coimbra, Portugal; Center for Innov…
- Allergology and Clinical Immunology Department, Hospitais da Universidade de Coimbra, Unidade Local de Saúde de Coimbra, Coimbra, Portugal; Faculty of Medicine, University of Coimbra, Coimbra, Portugal.
- Allergology and Clinical Immunology Department, Unidade Local de Saúde São João, Porto, Portugal.
Förderung
- Deutsche Forschungsgemeinschaft
Zitieren
APA
Marcelino, J. L. A., Metz, M., Pashuk, M., Xiang, Y. K., Scheffel, J., Pereira, H. S. P. A., Regateiro, F. E. C. S., Todo-Bom, A. M. P., Leão, L. R. C., Mota, D. M. T., Ferreira, R. D., Horta, A. D. D. S. F., Guimarães, J. F. M., Tomaz, E., & Muñoz, M. (2026). Complement C5 defines 2 chronic spontaneous urticaria endotypes with distinct autoantibody profiles and omalizumab responses: The INCA study. Annals of Allergy, Asthma & Immunology. https://doi.org/10.1016/j.anai.2026.08.033
Vancouver
Marcelino JLA, Metz M, Pashuk M, Xiang YK, Scheffel J, Pereira HSPA, et al. Complement C5 defines 2 chronic spontaneous urticaria endotypes with distinct autoantibody profiles and omalizumab responses: The INCA study. Annals of Allergy, Asthma & Immunology. 2026. doi:10.1016/j.anai.2026.08.033
BibTeX
@article{Marcelino2026,
author = {Marcelino, João Luís Alves and Metz, Martin and Pashuk, Margarita and Xiang, Yi-Kui and Scheffel, Jörg and Pereira, Helena Sofia Pires de Aguiar and Regateiro, Frederico Eugénio de Castro Soares and Todo-Bom, Ana Maria Pêgo and Leão, Leonor Rosário Carneiro and Mota, Diogo Miguel Teixeira and Ferreira, Ruben Duarte and Horta, Alice Dias Dos Santos Ferreira and Guimarães, Joana Filipa Marques and Tomaz, Elza and Muñoz, Melba},
title = {Complement C5 defines 2 chronic spontaneous urticaria endotypes with distinct autoantibody profiles and omalizumab responses: The INCA study},
journal = {Annals of Allergy, Asthma & Immunology},
year = {2026},
doi = {10.1016/j.anai.2026.08.033}
}
EUVIMED